Io­vance clos­es $172.5M of­fer­ing; Vek­lury ap­proved for Covid-19 pa­tients with se­vere re­nal dis­ease

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to un­der­writ­ers pitch­ing in.

Io­vance priced on Tues­day, of­fer­ing 20 mil­lion shares at $7.50 each, plus an ad­di­tion­al 3 mil­lion shares at the same price for un­der­writ­ers to pur­chase if they chose to. The $172.5 mil­lion rep­re­sents the gross amount be­fore ac­count­ing for un­der­writ­ing dis­counts, com­mis­sions and oth­er ex­pens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER